Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Daxxify Cervical Dystonia Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentCignaPolicy IP0588

    Botulinum Toxins - Daxxify

    Customize your policy alerts

    Sign up for Cigna Policy IP0588 alerts

    Get alerted when Policy IP0588 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and benefit coverage for Daxxify administered for cervical dystonia in adults. It establishes medical-necessity criteria, dosing limits, documentation requirements, noncovered cosmetic uses, and applicable billing code requirements.

    Policy Summary
    PayerCigna
    PolicyBotulinum Toxins - Daxxify
    Policy CodePolicy IP0588
    Change TypeMaterial revision
    Effective DateNovember 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with patient-specific documentation of cervical dystonia and the required clinical findings.
    SourceLink
    POLICY UPDATE CHANGES

    Cervical dystonia approval criteria were revised to require that the patient be at least 18 years old, have documented cervical dystonia, have documented sustained head torsion and/or tilt with limited neck range of motion, and receive prescribing by or consultation with a specified specialist.

    The maximum Daxxify dose for cervical dystonia was reduced from 300 units to 250 units, administered no more frequently than once every 3 months.

    The conditions-not-covered section was updated to focus on cosmetic uses.

    CPT code 64616 was removed from the coding information.

    1FDA-approved covered indication
    250 unitsMaximum dose per treatment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Every 3 monthsMinimum dosing interval
    1 yearApproval duration
    J0589Covered HCPCS billing code
    CosmeticNoncovered use category

    Covered and Noncovered Uses

    FDA-Approved Indication: Cervical Dystonia

    Daxxify is medically necessary and may be approved for 1 year when ALL of the following criteria are met:

    Cervical dystonia approval criteria

    • Age: Patient is at least 18 years of age≥ 18 years
    • Diagnosis: Patient has a diagnosis of cervical dystonia

      Documentation required.

    • Clinical findings: Patient has sustained head torsion and/or tilt with limited range of motion in the neck

      Documentation required.

    • Prescriber specialty: Daxxify is prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician

    Cosmetic use is not recommended for coverage because this indication is excluded under a typical medical benefit. Examples include facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid- and lower-face or neck rejuvenation, platysmal bands, and rejuvenation of the periorbital region.

    Daxxify for any use other than the covered cervical dystonia indication is considered not medically necessary, including cosmetic use.

    Medically Necessary Billing Code

    Medically Necessary HCPCS CodeHCPCSCovered
    J0589Injection, daxibotulinumtoxina-lanm, 1 unit

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Daxxify. Approval is recommended when the patient meets the policy criteria and dosing requirements; approvals are issued for the duration specified for the indication.

    • Requests for doses outside the established dosing may be reviewed case by case by a clinician, such as a Medical Director or Pharmacist.
    • When a dosing interval is stated in months, 1 month equals 30 days.
    Documentation Required

    Cervical Dystonia Documentation

    For cervical dystonia, submit patient-specific documentation supporting the diagnosis and required clinical findings. Documentation may include chart notes, laboratory tests, medical test results, claims records, or other relevant information, and must identify the patient.

    • Document a diagnosis of cervical dystonia (also known as spasmodic torticollis).

    Drug and Indication Background

    Daxxify (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for the treatment of cervical dystonia in adults. Cervical dystonia is also known as spasmodic torticollis.

    Policy Definitions

    Cervical Dystonia
    ConditionCervical dystonia
    Alternate nameSpasmodic torticollis
    Botulinum Toxin Potency Units
    Product specificityPotency units are specific to each botulinum toxin product.
    InterchangeabilityUnits are not interchangeable with units of another botulinum toxin product.
    ConversionUnits are not directly convertible to units of another botulinum toxin product.

    Initial Therapy Requirements

    Initial Therapy: Cervical Dystonia

    Initial approval is available for 1 year when all cervical dystonia criteria are met:

    Initial therapy for cervical dystonia

    • Age: Patient is at least 18 years of age≥ 18 years
    • Diagnosis: Patient has a documented diagnosis of cervical dystonia

      Documentation required.

    • Clinical findings: Patient has documented sustained head torsion and/or tilt with limited range of motion in the neck

      Documentation required.

    Daxxify Quantity Limit

    Quantity Limit
    DrugDaxxify
    Maximum dose250 units
    Administration frequencyNot more frequently than once every 3 months
    Policy Summary
    PayerCigna
    PolicyBotulinum Toxins - Daxxify
    Policy CodePolicy IP0588
    Change TypeMaterial revision
    Effective DateNovember 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with patient-specific documentation of cervical dystonia and the required clinical findings.
    SourceLink
    On This Page
    Covered and Noncovered UsesMedically Necessary Billing CodeAuthorization, Documentation, and Denial RisksDrug and Indication BackgroundPolicy DefinitionsInitial Therapy RequirementsDaxxify Quantity Limit
  1. Document sustained head torsion and/or tilt with limited range of motion in the neck.
  2. The patient must be at least 18 years old, and treatment must be prescribed by or provided in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician.
  3. Denial Risk

    Noncovered Uses, Coding, or Cosmetic Requests

    Coverage is not recommended for cosmetic use or other uses outside the covered indication. Claims may be denied when the billed condition, diagnosis, or procedure codes are not covered under the policy.

    • Cosmetic examples include facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid- and lower-face or neck rejuvenation, platysmal bands, and periorbital rejuvenation.
    • Use the most appropriate codes in effect on the submission date and submit covered diagnosis and procedure codes.
    Denial Risk

    Cervical Dystonia Criteria Not Met

    Cervical dystonia approval requires all policy criteria to be satisfied. Requests may be denied when the patient does not meet the age, diagnosis, clinical finding, or specialist prescribing/consultation requirements.

    • Patient is 18 years of age or older.
    • Documented diagnosis of cervical dystonia.
    • Documented sustained head torsion and/or tilt with limited neck range of motion.
    • Prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician.
    Denial Risk

    Dose or Frequency Exceeds Policy Limit

    The policy allows a maximum dose of 250 units administered no more frequently than once every 3 months. Requests exceeding the dose or frequency limit require case-by-case clinician review and are not automatically approved.

    • Doses above 250 units require review by a clinician, such as a Medical Director or Pharmacist.
    • Administration more frequently than once every 3 months requires case-by-case clinician review.
    • When the dosing interval is stated in months, 1 month equals 30 days.
  4. Specialist involvement: Daxxify is prescribed by or in consultation with a pain medicine specialist, neurologist, or physical medicine and rehabilitation physician